David Linetsky Sells 8,332 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) insider David Linetsky sold 8,332 shares of Phreesia stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $67,239.24. Following the completion of the sale, the insider owned 224,056 shares in the company, valued at approximately $1,808,131.92. This represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Linetsky also recently made the following trade(s):

• On Wednesday, March 18th, David Linetsky sold 107 shares of Phreesia stock. The stock was sold at an average price of $11.06, for a total value of $1,183.42.
• On Friday, January 16th, David Linetsky sold 6,038 shares of Phreesia stock. The stock was sold at an average price of $16.36, for a total value of $98,781.68.
• On Thursday, January 15th, David Linetsky sold 1,743 shares of Phreesia stock. The stock was sold at an average price of $16.38, for a total value of $28,550.34.

Phreesia Price Performance

Shares of PHR stock opened at $8.61 on Wednesday. The firm has a market cap of $523.14 million, a P/E ratio of 287.00 and a beta of 0.86. Phreesia, Inc. has a fifty-two week low of $7.77 and a fifty-two week high of $32.76. The business’s 50 day moving average price is $11.14 and its 200-day moving average price is $16.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The business had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a return on equity of 3.23% and a net margin of 0.48%.Phreesia’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.11) earnings per share. On average, equities research analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PHR has been the subject of a number of research analyst reports. Canaccord Genuity Group lowered their target price on Phreesia from $33.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Robert W. Baird restated a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a research note on Tuesday, March 31st. Barclays lowered their target price on Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, December 16th. KeyCorp lowered their target price on Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Royal Bank Of Canada initiated coverage on Phreesia in a research note on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 target price for the company. Twelve investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.82.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Phreesia by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company’s stock valued at $97,194,000 after buying an additional 39,540 shares during the last quarter. Greenhouse Funds LLLP raised its stake in Phreesia by 16.8% during the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after buying an additional 557,265 shares during the last quarter. Granahan Investment Management LLC raised its stake in Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after buying an additional 1,018,987 shares during the last quarter. Franklin Resources Inc. raised its stake in Phreesia by 28.8% during the fourth quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock valued at $33,841,000 after buying an additional 446,890 shares during the last quarter. Finally, Nuveen LLC raised its stake in Phreesia by 12.7% during the fourth quarter. Nuveen LLC now owns 1,875,725 shares of the company’s stock valued at $31,737,000 after buying an additional 211,262 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Named to Becker’s Hospital Review 2026 list of “Revenue Cycle Management Companies to Know,” a credibility signal for Phreesia’s patient intake/revenue-cycle positioning that can help sales conversations and customer wins. Becker’s Listing
• Positive Sentiment: Large institutional holders have recently added to positions (Vanguard, Granahan, Franklin, Nuveen among others), which supports liquidity and signals confidence from professional investors. Institutional Ownership Details
• Neutral Sentiment: Insiders David Linetsky and General Counsel Allison Hoffman sold shares (April 10) under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vesting awards; sales were disclosed via SEC Form 4 and appear planned rather than opportunistic. Insider Form 4
• Neutral Sentiment: Recent quarterly results showed revenue growth (~15.9% y/y) and revenue roughly in line with expectations, but an EPS miss (0.02 vs. est. 0.07) and analysts’ negative near‑term EPS outlook keep sentiment mixed. Earnings Summary
• Negative Sentiment: Investor‑protection firms (Pomerantz LLP and Levi & Korsinsky) announced investigations into Phreesia concerning potential securities law issues; such probes often weigh on sentiment and can increase legal/settlement risk. Pomerantz Investigation Levi & Korsinsky Notice
• Negative Sentiment: Multiple analysts have cut price targets recently (e.g., Stephens, Wells Fargo, Mizuho, Canaccord, Robert W. Baird); KeyCorp lowered its target to $12 while keeping an overweight rating — the cuts reflect skepticism about near‑term recovery and help explain the depressed stock valuation versus historical highs. Analyst Moves

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.